Rates of repeat EGD in nondiabetic adults with glucagon-like peptide-1 receptor agonist prescription: a retrospective matched cohort study - 29/11/24

Doi : 10.1016/j.gie.2024.10.004

Abbinaya Elangovan, MD ¹, Pearl Aggarwal, MD ², David C. Kaelber, MD ³, Raj Shah, MD ^4,^⁎
¹ Division of Gastroenterology, University Hospitals Cleveland Medical Center; Case Western Reserve University, Cleveland, Ohio, USA
² Division of Gastroenterology, University Hospitals Cleveland Medical Center; Case Western Reserve University, Cleveland, Ohio, USA
³ Division of Gastroenterology, University Hospitals Cleveland Medical Center; Case Western Reserve University, Cleveland, Ohio, USA
⁴ Division of Gastroenterology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Columbus, Ohio, USA

^∗Reprint requests: Raj Shah, MD, Department of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210.Department of GastroenterologyHepatology and NutritionThe Ohio State University Wexner Medical Center410 W 10th AveColumbusOH43210

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 29 November 2024
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Background and Aims

Data on endoscopic outcomes in adults without diabetes who are taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) are limited. Therefore, we compared repeat EGD in this population with those not taking GLP-1RAs using a retrospective matched case-control study.

Methods

Using the TriNetX health research platform (Cambridge, Mass, USA), we analyzed adults with a body mass index ≥27 kg/m² without diabetes who underwent diagnostic EGD. The study group included individuals with ≥3 GLP-1RA prescriptions and undergoing EGD ≥30 days after the initial GLP-1RA prescription. The control group included individuals who were never prescribed GLP-1RAs but had an EGD after the prescription of other weight loss medications. Outcomes were compared using the risk ratio (RR) in matched cohorts.

Results

No significant difference in repeat EGD (5.4% vs 4.2%; RR, 1.28; 95% confidence interval [CI], .95-1.71) or new diagnosis of gastroparesis (1.1% vs .6%; RR; 2.00; 95% CI, .94-4.27) was noted between the groups.

Conclusions

GLP-1RAs may not substantially increase the risk of repeat endoscopy in individuals without diabetes.

Le texte complet de cet article est disponible en PDF.

Abbreviations : CI, BMI, CPT, FDA, GLP-1RA, ICD-10-CM, RR

Plan

DIVERSITY, EQUITY, AND INCLUSION: The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.